Nimustine
Based on 1 publication(s) in Google Scholar
Nimustine is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 42471-28-3
- Formule: C9H13ClN6O2
- Masse moléculaire:272.69
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Nimustine
MoreVoir tous les produits spécifiques à Isoform DNA/RNA Synthesis
MoreVoir tous les produits spécifiques à Isoform AP-1
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SF-126 | IC50 |
310 μM
Compound: ACNU
|
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
|
[PMID: 27041398] |
| SF-126 | IC50 |
320 μM
Compound: ACNU
|
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
|
[PMID: 27041398] |
| SF-126 | IC50 |
360 μM
Compound: ACNU
|
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
|
[PMID: 28197307] |
| SF-126 | IC50 |
450 μM
Compound: ACNU
|
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
|
[PMID: 28197307] |
| U-87MG ATCC | IC50 |
0.84 μM
Compound: Nimustine
|
Cytotoxicity against human U87MG cells after 72 hrs by MTT assay
Cytotoxicity against human U87MG cells after 72 hrs by MTT assay
|
[PMID: 20184290] |
Nimustine (50 μM, 72 h) activates caspase and AP-1, upregulates the expression of bim, promotes the phosphorylation of c-Jun, and induces apoptosis in cell LN-229[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LN-229 cell line
-
Concentration:50 μM
-
Incubation Time:72-120 hours
-
Result:Time-dependently induced apoptosis.
-
Cell Line:LN-229
-
Concentration:50 μM
-
Incubation Time:24-120 hours
-
Result:Increased the expressions of cleaved of bim and caspase-3/8/9.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C3H/HeN mice with solid FM3A tumors[2]
-
Dosage:15 and 30 mg/kg
-
Administration:iv, every two weeks for 2 doses (30 mg/kg), or once weekly for 4 doses (15 mg/kg)
-
Result:Inhibited tumor growth. Caused weight loss and white blood cell (WBC) depression.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 42471-28-3
-
Masse moléculaire 272.69
-
Formule C9H13ClN6O2
-
SMILES
O=C(NCC1=CN=C(C)N=C1N)N(CCCl)N=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
ACS Appl Mater Interfaces
Multi-Inlet Spheroid Generator for High-Throughput Combinatorial Drug Screening Based on the Tumor Microenvironment. [Abstract]2023 Jul 12;15(27):32087-32098. PMID: 37234040
Pureté et documentation
Références
[1]. Tomicic MT, et al. Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. Oncotarget. 2015 Oct 20;6(32):33755-68. [Content Brief]
[2]. Shimizu F, et al. Effects of combined treatment with nimustine hydrochloride and radiation on solid FM3A tumor in mice. Jpn J Cancer Res. 1987 Jul;78(7):756-62. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nimustine Related Classifications
HY-13703 Related Classifications
Powered by Bioz